07:40 AM EDT, 07/24/2026 (MT Newswires) -- The European Medicines Agency's Committee for Medicinal Products for Human Use recommended the approval of Accord Healthcare's Tafamidis Accord, a generic of Vyndaqel. Tafamidis Accord, available as 61-milligram capsules containing the active substance tafamidis, is intended for the treatment of hereditary transthyretin amyloidosis in adult patients with cardiomyopathy, according to a Friday notice. The European Commission will now decide whether to grant a marketing authorization for the pharmaceutical company's generic drug.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.